146 related articles for article (PubMed ID: 34954701)
21. Management outcome of acute urinary retention: model of prediction.
Daly P; Connolly S; Rogers E; Sweeney P
Urol Int; 2009; 83(1):39-43. PubMed ID: 19641357
[TBL] [Abstract][Full Text] [Related]
22. Factors predicting the success of a trial without catheter in acute urinary retention secondary to benign prostatic hyperplasia.
Bhomi KK; Bhattachan CL
Nepal Med Coll J; 2011 Sep; 13(3):178-81. PubMed ID: 22808810
[TBL] [Abstract][Full Text] [Related]
23. Alfuzosin 10 mg once daily in the management of acute urinary retention: results of a double-blind placebo-controlled study.
McNeill SA; Hargreave TB; Roehrborn CG;
Urology; 2005 Jan; 65(1):83-9; discussion 89-90. PubMed ID: 15667868
[TBL] [Abstract][Full Text] [Related]
24. A prospective study of conservatively managed acute urinary retention: prostate size matters.
Kumar V; Marr C; Bhuvangiri A; Irwin P
BJU Int; 2000 Nov; 86(7):816-9. PubMed ID: 11069406
[TBL] [Abstract][Full Text] [Related]
25. The efficacy of in-and-out catheterization as a way of trial without catheterization strategy for treatment of acute urinary retention induced by benign prostate hyperplasia: variables predicting success outcome.
Ko YH; Kim JW; Kang SG; Jang HA; Kang SH; Park HS; Moon du G; Cheon J; Kim JJ; Lee JG
Neurourol Urodyn; 2012 Apr; 31(4):460-4. PubMed ID: 22331691
[TBL] [Abstract][Full Text] [Related]
26. Randomised, placebo controlled, double blind study of alfuzosin SR in patients undergoing trial without catheter following acute urinary retention.
Shah T; Palit V; Biyani S; Elmasry Y; Puri R; Flannigan GM
Eur Urol; 2002 Oct; 42(4):329-32; discussion 332. PubMed ID: 12361896
[TBL] [Abstract][Full Text] [Related]
27. A prospective pilot study to validate the management protocol for patients presenting with acute urinary retention: a community-based, nonhospitalised protocol.
Gopi SS; Goodman CM; Robertson A; Byrne DJ
ScientificWorldJournal; 2006 Jun; 6():2436-41. PubMed ID: 17619714
[TBL] [Abstract][Full Text] [Related]
28. Alfuzosin once daily facilitates return to voiding in patients in acute urinary retention.
McNeill SA; Hargreave TB;
J Urol; 2004 Jun; 171(6 Pt 1):2316-20. PubMed ID: 15126812
[TBL] [Abstract][Full Text] [Related]
29. Evaluation of the impact of a clinical pathway on the progression of acute urinary retention.
Gas J; Liaigre-Ramos A; Caubet-Kamar N; Beauval JB; Lesourd M; Prudhomme T; Huyghe E; Soulié M; Charpentier S; Gamé X
Neurourol Urodyn; 2019 Jan; 38(1):387-392. PubMed ID: 30418678
[TBL] [Abstract][Full Text] [Related]
30. Ultrasound prostate parameters as predictors of successful trial without catheter after acute urinary retention in patients ongoing medical treatment for benign prostatic hyperplasia: a prospective multicenter study.
DE Nunzio C; Voglino O; Cicione A; Tema G; Cindolo L; Bada M; Lombardo R; Nacchia A; Trucchi A; Ships L; Gacci M; Milanesi M; Cito G; Serni S; Tubaro A
Minerva Urol Nephrol; 2021 Oct; 73(5):625-630. PubMed ID: 33200904
[TBL] [Abstract][Full Text] [Related]
31. Prospective randomized placebo-controlled study to assess the safety and efficacy of silodosin in the management of acute urinary retention.
Kumar S; Tiwari DP; Ganesamoni R; Singh SK
Urology; 2013 Jul; 82(1):171-5. PubMed ID: 23561712
[TBL] [Abstract][Full Text] [Related]
32. Admission of patients with acute urinary retention leads to a definitive management decision.
Ryan PC; Ryan ÉJ; Keenan RA; Haroon UM; Broe MP; Forde JC; Galvin D; Lennon GM; Murphy M; Quinlan DM; Mulvin DW
Ir J Med Sci; 2020 Aug; 189(3):999-1003. PubMed ID: 31858451
[TBL] [Abstract][Full Text] [Related]
33. Benign prostatic hyperplasia: mode of presentation and postoperative outcome.
Khan M; Khan AL; Khan S; Nawaz H
J Pak Med Assoc; 2005 Jan; 55(1):20-3. PubMed ID: 15816691
[TBL] [Abstract][Full Text] [Related]
34. A comparative study on the use of tamsulosin versus alfuzosin in spontaneous micturition recovery after transurethral catheter removal in patients with benign prostatic growth.
Maldonado-Ávila M; Manzanilla-García HA; Sierra-Ramírez JA; Carrillo-Ruiz JD; González-Valle JC; Rosas-Nava E; Guzman-Esquivel J; Labra-Salgado IR
Int Urol Nephrol; 2014 Apr; 46(4):687-90. PubMed ID: 24061764
[TBL] [Abstract][Full Text] [Related]
35. Α₁-blockers in the management of acute urinary retention secondary to benign prostatic hyperplasia: a systematic review and meta-analysis.
Guang-Jun D; Feng-Bin G; Xun-Bo J
Ir J Med Sci; 2015 Mar; 184(1):23-30. PubMed ID: 24599498
[TBL] [Abstract][Full Text] [Related]
36. Comparing effects of alpha-blocker management on acute urinary retention secondary to benign prostatic hyperplasia: A systematic review and network meta-analysis.
Gwon YN; Park JJ; Yang WJ; Doo SW; Kim JH; Kim DK
Prostate Int; 2023 Jun; 11(2):91-99. PubMed ID: 37409094
[TBL] [Abstract][Full Text] [Related]
37. Management of acute urinary retention.
Fitzpatrick JM; Kirby RS
BJU Int; 2006 Apr; 97 Suppl 2():16-20; discussion 21-2. PubMed ID: 16507048
[TBL] [Abstract][Full Text] [Related]
38. Intermittent catheterization time required after interstitial laser coagulation of the prostate.
Nishizawa K; Kobayashi T; Mitsumori K; Watanabe J; Ogura K
Urology; 2004 Jul; 64(1):79-83. PubMed ID: 15245940
[TBL] [Abstract][Full Text] [Related]
39. Efficacy of doxazosin in the treatment of acute urinary retention due to benign prostate hyperplasia.
Prieto L; Romero J; López C; Ortiz M; Pacheco JJ
Urol Int; 2008; 81(1):66-71. PubMed ID: 18645274
[TBL] [Abstract][Full Text] [Related]
40. The economic impact of using alfuzosin 10 mg once daily in the management of acute urinary retention in the UK: a 6-month analysis.
Annemans L; Cleemput I; Lamotte M; McNeill A; Hargreave T
BJU Int; 2005 Sep; 96(4):566-71. PubMed ID: 16104911
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
